Article Impact Level: HIGH Data Quality: STRONG Summary of JACC https://doi.org/10.1016/j.jacc.2026.09.018 Dr. Behnood Bikdeli et al.
Points
- Researchers published a special communication in the Journal of the American College of Cardiology evaluating clinical trial evidence comparing left atrial appendage closure with oral anticoagulation for atrial fibrillation.
- Despite atrial fibrillation affecting approximately fifty nine million individuals globally and over six hundred thousand closure procedures performed worldwide randomized trial evidence encompasses just over seven thousand patients.
- Rigorous literature analysis revealed substantial methodological heterogeneity across trials including reliance on non inferiority designs outdated warfarin comparators and varying clinical endpoints that preclude reliable meta analytic pooling.
- Investigators highlighted ongoing procedural and post operative risks including device related thrombosis and increased venous blood clots following the cessation of systemic blood thinning medications.
- Authors concluded that because oral anticoagulants possess substantially stronger evidence left atrial appendage closure should be reserved for carefully selected patients through multidisciplinary shared decision making.
Summary
This special communication evaluated the clinical evidence base comparing left atrial appendage closure (LAAC) with oral anticoagulation for stroke prevention in patients with atrial fibrillation (AF). Published in the Journal of the American College of Cardiology (JACC), the review addressed the growing divergence between clinical adoption and trial data, given that AF affects roughly 10 million adults in the United States and 59 million globally. While direct oral anticoagulants (DOACs) serve as the primary therapeutic cornerstone to mitigate ischemic stroke and systemic embolism, the researchers sought to rigorously appraise LAAC trials to establish an objective clinical decision-making framework for patients unable or unwilling to sustain long-term anticoagulation.
Through a systematic literature evaluation, the investigators identified a pronounced disparity between global procedural volume—exceeding 600,000 LAAC procedures performed worldwide—and the underlying randomized clinical trial cohort, which encompasses just over 7,000 patients. The review highlighted substantial heterogeneity across existing trials regarding patient populations, procedural techniques, control comparators—many utilizing outdated vitamin-K antagonists like warfarin rather than modern DOACs—and clinical endpoints, precluding reliable meta-analytic pooling. Furthermore, nearly all trials relied on non-inferiority designs with complex bias considerations, while raising safety concerns such as device-related thrombosis and elevated venous thromboembolism risk following post-procedural anticoagulation cessation.
The authors conclude that the evidentiary support for oral anticoagulation remains substantially stronger than that for LAAC, which entails upfront procedural risks and costs particularly relevant to frail or multimorbid patients. Consequently, LAAC should be reserved for carefully selected AF patients with clear contraindications to anticoagulation, guided by multidisciplinary shared decision-making between proceduralists and non-procedural electrophysiologists or cardiologists while awaiting more definitive randomized trial data.
Link to the article: https://www.jacc.org/doi/10.1016/j.jacc.2026.09.018?__cf_chl_tk=M8Koh3FCM73FJdg9BZW1KT7O_qDCg6ljW2gHFiIesIY-1794905683-1.0.1.1-Ncj0gqUkH.RKFLwYIEISatm77TLt0KiwIHBrGfA0zew
References
Bikdeli, B., Arun, A. S., Pawar, S., Dhruva, S. S., Butala, N. M., Yong, C., Spatz, E. S., Cohen, D. J., Bittl, J. A., Albert, C. M., Leon, M. B., Makkar, R. R., Nazarian, S., Krumholz, H. M., & Gupta, A. (2026). Left atrial appendage closure or anticoagulation for atrial fibrillation. JACC, S0735109726077764. https://doi.org/10.1016/j.jacc.2026.09.018
